DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this study is to

• evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes

• evaluate how the above mentioned treatments influence the immune system of the subjects and interact with any viral infections

• evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd) plus Vitamin D on the immune system, viral infections, and on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnny Ludvigsson
• Collaborators: Diamyd Medical AB; Sahlgrenska University Hospital, Sweden; Swedish Child Diabetes Foundation; The Research Council of South East Sweden (FORSS)
• Treatments: Aluminum sulfate; Ergocalciferols; Ibuprofen; Insulin; Vitamin D; Vitamins

Criteria

Main Inclusion Criteria:

• Male and female patients between 10 and 18 years of age

• Insulin dependent Type 1 Diabetes mellitus diagnosed within the previous 4 months at time of screening

• Fasting C-peptide level at time of screening above or equal to 0.12 nmol/L

• Elevated GAD65 antibodies (GADA) at time of screening

Main Exclusion Criteria:

• Treatment with immunosuppressants, continuous anti-inflammatory drug, Vitamin D or any anti-diabetic medications other than insulin

• A history of certain diseases or conditions (e.g. anemia, HIV, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc)

• Treatment with any vaccine within 4 months prior to first planned administration of GAD-Alum/placebo or planned treatment with vaccine up to 4 months after the last injections with GAD-Alum/Placebo, including influenza vaccines

• Participation in other clinical trials with a new chemical entity within the previous 3 months

• Pregnancy or planned pregnancy within 1 year after the last GAD-Alum/placebo dose

• Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study